Lilli received a bachelor of science in chemistry and biology from MIT and her MD and PhD from Albert Einstein College of Medicine. She did her internship and residency training in Internal Medicine and her fellowship in Hematology at the Brigham and Women’s Hospital and Harvard Medical School in Boston. From 1994 until 2007, she was a faculty member and associate professor in the department of Hematology and Oncology at the University of Michigan where she established a laboratory-based research program focused on the regulation of integrin-dependent adhesion in leukocytes and a clinical practice specializing in hematologic malignancies.
Lilli began her career in the pharmaceutical industry at Millennium in 2007, where she played a key role in the development of the Nedd-8 activating enzyme inhibitor and the oral second-generation proteasome inhibitor, Ninlaro. She joined Novartis in 2009 as a physician focusing on translational medicine in oncology and had increasing roles of responsibility most recently leading Translational Clinical Oncology group since 2014. There she oversaw the development of the early oncology pipeline including the registration study for the ALK inhibitor Zykadia, the early development of Kisqali, the development a novel BCR-ABL inhibitor, ABL001, and the entire pre-PoC target and immune-oncology portfolios. In November of 2019, she joined Incyte to lead their early clinical development programs.